RxDoctor Payments Data

Kristin Rood

Family · West Branch, IANPI 1922590132

Payments from drug & device makers

$1,020in general payments, 2019–2025

Across 14 payments — averaging $72.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$169
  • Novo Nordisk$164
  • Lilly USA, LLC$162
  • AbbVie$123
  • Otsuka America Pharmaceutical, Inc.$122
  • Merck$83
  • plus $197 from 5 others

What the payments were for

  • Food & beverage$1,020100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,020 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$62,594
Medicare patients
236
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$84,856
EliquisApixaban23$34,656
JardianceEmpagliflozin29$28,870
XareltoRivaroxaban13$17,302
MounjaroTirzepatide15$15,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,867
TrulicityDulaglutide13$11,749
Breo ElliptaFluticasone/Vilanterol13$7,821
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,256
SymbicortBudesonide/Formoterol Fumarate16$3,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$2,912
Bupropion XlBupropion Hcl39$2,784
Ventolin HfaAlbuterol Sulfate22$2,425
Albuterol Sulfate HfaAlbuterol Sulfate78$1,805
Atorvastatin Calcium224$1,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$164$84,85676 claims
Boehringer IngelheimJardiance$65$28,87029 claims
Lilly USA, LLCMounjaro, Trulicity$162$27,21928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in West Branch

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →